Aurobindo Pharma’s arm to acquire 20% additional ownership in Luoxin Aurovitas

23 Dec 2025 Evaluate

Aurobindo Pharma’s wholly owned subsidiary -- Helix Healthcare B.V, has entered into a binding agreement on December 22, 2025 with Shandong Luoxin Pharmaceutical Group Stock Co., China (Shandong Luoxin), the joint venture partner in Luoxin Aurovitas Pharma (Chengdu) Co., China (Luoxin Aurovitas), a 30:70 joint venture company between Helix and Shandong Luoxin, to acquire 20% additional ownership in Luoxin Aurovitas. 

The object of acquisition is to expand the manufacturing to economies of scale by adding 2 high Speed Lines and cater market demand. Cost of acquisition is $5.12 million. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1205.95 -6.70 (-0.55%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×